Xcovery: A Company With a Mission

Welcome to Xcovery, an evidence-based, innovation-driven biopharmaceutical company aiming to improve the lives of people around the world living with advanced stages of cancer.

Passion for science

At Xcovery, our mission is simple: to employ advanced science to create leading-edge oncology therapies that are not only more effective than current options but are also less toxic and more tolerable for those who need them.

ALK (anaplastic lymphoma kinase) is a receptor tyrosine kinase that was first identified
as part of a chromosomal rearrangement in anaplastic large cell lymphoma. Abnormal
forms of ALK are key drivers of certain types of non-small cell lung cancer and neurobl-
astomas. Ensartinib is a potent inhibitor of ALK with promising clinical antitumor activity.

The ability to stimulate new blood vessel formation, or angiogenesis, is critical for normal tissue growth as well as tumor growth. Growth factors, such as vascular endothelial growth factor (VEGF), promote vessel growth as well as immune suppression. Vorolanib is a next-generation orally active multikinase inhibitor with activity against the VEGF receptor and angiogenesis. In monotherapy and in combination therapy, vorolanib has shown efficacy against several cancers.

Xcovery is seeking partners to launch ensartinib in the United States and globally and to develop vorolanib as the ideal combination partner for an immuno-oncology therapy for various tumor types.

Xcovery is seeking investors who recognize that targeted therapeutics in oncology offer some of the highest values.

Xcovery: A Company With a Mission

Passion for science

Ensartinib:

Potentially the best-in-class ALK inhibitor

Vorolanib:

A next-generation multikinase angiogenesis inhibitor

Partnerships

Investors